Phase II study of Irinotecan, TS-1 and Bevacizumab as second-line treatment in patients with advanced colorectal cancer (KMOG 0708)

ABSTRACT: Interventions: TS-1+CPT-11+Bevacizumab Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

DISEASE(S): Advanced Colorectal Cancer

PROVIDER: 2617282 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR